• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
    • Our Impact
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Interactive Tool
    • Other Educational Tools
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
  • Donate
  • Contact
  • Show SearchSearch

Finasteride

May 1, 2024

Selected References:

  • Ahn KH, et al. 2015. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case-series. J Clin Toxicol 5:2
  • AlSaad D, et al. 2018. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm 40(4): 803-805.
  • Amory JK, et al. 2007. The effect of 5- alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 92:1659-1665.
  • Anderson CA, Clark RL. 1990. External genitalia of the rat: normal development and the histogenesis of 5 alpha-reductase inhibitor-induced abnormalities. Teratology;42:483-496.
  • Bowman CJ, et al. 2003. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci; 74:393-406.
  • Carlin JR, et al. 1992. Disposition and pharmacokinetics of (14C) finasteride after oral administration in humans. Drug Metab Dispos Biol Fate Chem; 20:148-55.
  • Cather JC, et al. 1999. Finasteride – An update and review. Cutis 64:167-172.
  • Ciotta L, et al. 1995. Clinical and endocrine effects of finasteride, a 5(alpha)-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 64:299-306.
  • Clark RL, Anderson CA, Prahalada S et al: Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5(alpha)-reductase inhibitor. Toxicol Appl Pharmacol 119:34-40.
  • Clark RL, et al. 1990. External genital abnormalities in male rats exposed in utero to finasteride, a 5-alpha reductase inhibitor. Teratology; 42:91-100.
  • Falsetti L, et al. 1997. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecol Endocrinol 11:251-157.
  • Husmann DA, McPhaul MJ. 1991. Time-specific androgen blockade with flutamide inhibits testicular descent in the rat. Endocrinology; 129:1409-1416.
  • Gupta AK & Talukder M. 2022. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?. Journal of cosmetic dermatology, 21(5), 1841–1848.
  • Khera M, et al. 2020. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. Transl Androl URol 9(3): 1201-1209.
  • Kohler C, et al. 2007. Effect of finasteride 5mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol; 23:142-145.
  • Kurzrock EA, et al. 2000. Urethral development in the fetal rabbit and induction of hypospadias: a model for human development. J Urol 164(5):1786-1792.
  • Laborde, E. and R. E. Brannigan. 2010. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. J Androl; 31(2): e1-2.
  • Lumachi F, Rondinone R. 2003. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 79:942-946.
  • Martinez AG, et al. 2011. Effects of in utero exposure to D-004, a lipid extract from Roystonea regia fruits, in the male rat: a comparison with finasteride. J Med Food. Dec;14(12):1663-9.
  • Overstreet JW, et al. 1999. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 162:1295-1300.
  • Paris JJ, et al. 2011. Inhibition of 5 alpha reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progestogen milieu of juvenile rat offspring. J Neuroendocrinol; 23(11): 1079-90.
  • Prahalada S, et al. 1997. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the Rhesus monkey (Macaca mulatta). Teratology; 55:119-31.
  • Propecia prescribing information. 2020. Accessible from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e07adb4-7807-47d3-b9a9-2332a3047410#S12.3
  • Ricci G, et al. 2012. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol; 11(12):1511-3.
  • Rittmaster, RS, 1994. Drug Therapy: Finasteride. New Engl J Med 330:120-125.
  • Salvarci A, Istanbulluoglu O. 2013. Secondary infertility due to use of low-dose finasteride. Int Urol Nephrol; 45(1):83-
  • Samplaski MK, et al. 2013. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertility and Sterility; 100:1528-1529.
  • Spencer JR, et al. 1991. Effects of flutamide and finasteride on rat testicular descent. Endocrinology; 129:741-748.
  • Teichert M, et al. 2017. Contraindicated use of 5-alpha-reductase inhibitors in women. Br J Clin Pharmacol. 83(2): 429-431
  • Wise LD, et al. 1991. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5-alpha-reductase inhibitor. Reprod Toxicol 5:353-362

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Constipation
  • Coronavirus (COVID-19)
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2025 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.